While the EORTC QLQ-C30 is an important tool for assessing the generic aspects of QOL, it has limitations and therefore a modular approach was adopted for disease-specific treatment measurements. An essential aspect of the "modular" approach to QOL assessment adopted by the EORTC QLG (Quality of Life Group) is the development of modules specific to tumour site, treatment modality, or a QOL dimension, to be administered in addition to the core questionnaire (EORTC QLQ-C30). The modules, like the core questionnaire, are designed for use in cancer clinical trials.
Since individual members or subgroups of the QLG are involved in module development, guidelines are needed and these have been developed to standardize the module development process. This ensures uniformly high quality across modules.
The term "module" is defined, the composition of modules is sketched, the attributes of modules are specified and the module development process is described in detail in the " Guidelines for Developing Questionnaire Modules".
The download request on this website is for academic use only.
For studies carried out by a commercial sponsor or if your study is being wholly or partially sponsored (funded, organized, initiated, managed or run) by the pharmaceutical industry, a compensation fee is payable. A compensation fee is required per study. The amount of the fee depends on the number of patients. For further details for commercial use, please contact Christopher Courtois directly.
Thank you for your understanding.
Overview of the Module Development Schema
VALIDATED MODULES SPECIFIC DISEASES
Click on the module to see a specimen